Orasis Pharmaceuticals launches Qlosi for presbyopia treatment in the U.S.

Orasis Pharmaceuticals has announced the U.S. availability of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel prescription eye drop designed to treat presbyopia, or age-related blurry near vision, according to a company press release. Qlosi features the company’s proprietary EyeQ Formulation, which optimizes efficacy while minimizing side effects. The formulation...